Saturday October 6

Print this page

View scientific program here (interactive) or here (pdf)

View the synoptic here

07h30 Welcoming coffee


Epidemiology, genetics and pathophysiology of valvular diseases
Moderators: Per Eriksson & Victor Legrand

08.00 Genetics and pathophysiology of bicuspid and tricuspid aortic valve disease. What we learned from the ASAP study?
Per Eriksson

08.15 Biomechanical implications of bicuspid aortic valve
Alessandro Della Corte

08.30 Aortic root morphology in bicuspid and tricuspid aortic valve surgery
Anders Franco-Cereceda

08.45 Paradoxical low flow low gradient in aortic valve stenosis
Jean Dumesnil

09.00 Talks selected from submitted abstracts

09.00 Simultaneous detection of elevated matrix metalloproteinases in ascending aortic aneurysms in patients with bicuspid aortic valve disease
Mohamed Salah

09.05 Early cell changes and transforming-growth-factor-beta pathway alterations in  the aortopathy associated with bicuspid aortic valve stenosis
M. Buonocore

09.10 Valve morphotype and aortic phenotype affect the progression of aortic dilatation in bicuspid aortic valve associated aortopathy
V. D’Oria

09.15 Clinical and echographic predictive values of the dilated aorta in patients with bicuspid aortic valve
Laure Gilis

09.20 Discussion

09.45 Coffee break



Clinical management and treatment of valvular diseases
Victor Legrand & Marc A. Radermecker

10.15 New ESC/EACTS guidelines in the management of asymptomatic severe aortic stenosis
Luc Pierard

10.35 TAVI indication and management of complications
Carlo Di Mario

10.55 Factors influencing the long term results of aortic valvuloplasty
Gebrine El Khoury

11.15 Talks selected from submitted abstracts

11.15 Surgical treatment of ascending aortic aneurysms in patients with bicuspid aortic valve disease
Vitalii Kravchenko

11.20 Subclavian TAVI: a single centre experience
KJ Griffin

11.25 Discussion
11.30 Debate and interactive discussions:
- Clinical case debate: for/against

Victor Legrand

- Aortic stenosis in octogenarian: TAVI vs. Surgery
Inez Rodrigus

12.00 Lunch

13.00 Symposium
Perceval™ S. The Truly Sutureless Valve: 5-years Clinical Results And First BeNeLux Results
Jean-Olivier Defraigne

13.00 5-Years European Clinical Results with Perceval™ S
Bart Meuris

13.10 First Experiences with Perceval™ S.
Jean-Marc Marnette

13.20 A single center experience with Perceval in Maastricht
S. Kats

13.30 Minimal invasive approach trough Right-minithoracotomy: First Experiences
Mattia Glauber

13.40 Closing Remarks
Jean-Olivier Defraigne



Recent advances and future directions of aortic diseases
Moderator: Frank Lederle


14.00 Why the EVAR trials are misleading: EVAR is better than open repair in fit and unfit patients
Frank Veith

14.15 Introduction of AAA healing by a short administration of cyclosporine A: from the lab to a clinical trial in France
Eric Allaire

14.30 18 months doxycycline therapy for AAA stabilization: results of the Pharmaceutical Aneurysm Stabilization Trial (PHAST)
Jan Lindeman

14.45 AAA and inflammation: the problem or the solution?
Jan Lindeman

15.00 Final results of the VA Open vs. Endovascular Repair (OVER) trial for AAA
Frank Lederle

15.15 Does PET scan reliably predict AAA rupture?
Natzi Sakalihasan

15.30 The biomechanical AAA rupture risk
Christian Gasser

15.45 Regional mechanical properties of AAA tissue and finite element analysis of rupture risk
Tim McGloughlin

16.00 The role of HDL in AAA: a nation-wide case control study (N=50000) and a prospective cohort growth study of AAA diagnosed by population-based
screening (N=500)

Jes Lindholt

16.15 Discussion

16.35 Talks selected from submitted abstracts

16.35 Multidimensional analysis of growth of small Abdominal Aortic Aneurysms
Giampaolo Martufi

16.40 Multifactorial relationship between 18F-fluoro-deoxy-glucose positron emission tomography signalling and wall stress in unruptured aortic aneurysms
Alain Nchimi

16.45 The vitamin D receptor (VDR) is a weak moderator of vascular inflammation. A study of the abdominal aortic aneurysm
Arend-Jan Nieuwland

16.50 Sorafenib inhibits angiotensin II-induced aneurysm formation and progression in Apolipoprotein E-deficient mice
Badri Vijaynagar

16.55 Thiazolidinediones prevent aortic aneurysm and rupture: understanding the mechanism of action
Nicoletta Charolidi

17.00 Measuring the maximum diameter of native abdominal aortic aneurysms: review and critical analysis
Laurence Rouet

17.05 Young investigator awards and concluding remarks
Helena Kuivaniemi and Jean-Olivier Defraigne

17.30 Adjournment